PD-1/PD-L1-IN-10

Cat. No. M29673

All AbMole products are for research use only, cannot be used for human consumption.

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.

PD-1/PD-L1-IN-10 (compound B2) is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy.

Molecular Weight	581.62
Formula	C33H31N3O7
CAS Number	2487550-41-2
Form	Solid
Solubility (25°C)	DMSO 100 mg/mL (ultrasonic)
Storage	Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month

Related PD-1/PD-L1 Products
PD-1/PD-L1-IN-9 PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model.
NSC622608 NSC622608 is a V-domain Ig suppressor of T-cell activation (VISTA) ligand with an IC50 value of 4.8 μM.
PD-L1-IN-1 PD-L1-IN-1 is a potent PD-L1 inhibitor with an IC50 of 115 nM.
SL-279252 SL-279252 (PD1-Fc-OX40L) is a hexameric, bi-functional fusion protein with an ECD of PD-1 (70 pM affinity to PD-L1) linked to the ECD of OX40L (324 pM affinity for OX40) through an Fc linker. SL-279252 exhibited linear PK at doses up to 3.0 mg/kg, and a greater than proportional increase in AUC was observed at 6.0 mg/kg suggesting potential receptor saturation. The preliminary half-life is approximately 23 hours.
Rosnilimab Rosnilimab is a novel PD-1 checkpoint agonist antibody that reduces overactive T cell inflammation. Rosnilimab optimizes PD-1+ T cell inhibitory signaling by enabling tight immune synapse formation. Rosnilimab restores immune balance bringing T cell composition to a less activated state.

Catalog